Induction by carrageenan inflammation of prepronociceptin mRNA in VR1-immunoreactive neurons in rat dorsal root ganglia

Itoh, Masayuki; Takasaki, Ichiro; Andoh, Tsugunobu; Nishimura, Hiroshi; Tominaga, Makoto; Kuraishi, Yasushi

doi:10.1016/s0168-0102(01)00230-9

Cited by 32 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, SR16835, which is inactive in blocking tail flick acute pain, was able to attenuate SNL-induced mechanical allodynia, an action also blocked by SB-612111 (Khroyan et al, 2011). These results are consistent with chronic pain-, as well as chronic inflammation-induced changes in the levels of NOP receptor mRNA, N/OFQ peptide levels, and ppN/OFQ mRNA levels in rodents (Andoh et al, 1997;Itoh et al, 2001;Briscini et al, 2002;Witta et al, 2003) and humans (Raffaeli et al, 2006) and once again suggest that NOP agonists might have better success in treatment of chronic or inflammatory rather than nociceptive acute pain.…”

Section: B Bifunctional Compoundssupporting

confidence: 76%

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems

et al. 2016

View full text Add to dashboard Cite

The NOP receptor (nociceptin/orphanin FQ opioid peptide receptor) is the most recently discovered member of the opioid receptor family and, together with its endogenous ligand, N/OFQ, make up the fourth members of the opioid receptor and opioid peptide family. Because of its more recent discovery, an understanding of the cellular and behavioral actions induced by NOP receptor activation are less well developed than for the other members of the opioid receptor family. All of these factors are important because NOP receptor activation has a clear modulatory role on mu opioid receptor-mediated actions and thereby affects opioid analgesia, tolerance development, and reward. In addition to opioid modulatory actions, NOP receptor activation has important effects on motor function and other physiologic processes. This review discusses how NOP pharmacology intersects, contrasts, and interacts with the mu opioid receptor in terms of tertiary structure and mechanism of receptor activation; location of receptors in the central nervous system; mechanisms of desensitization and downregulation; cellular actions; intracellular signal transduction pathways; and behavioral actions with respect to analgesia, tolerance, dependence, and reward. This is followed by a discussion of the agonists and antagonists that have most contributed to our current knowledge. Because NOP receptors are highly expressed in brain and spinal cord and NOP receptor activation sometimes synergizes with mu receptor-mediated actions and sometimes opposes them, an understanding of NOP receptor pharmacology in the context of these interactions with the opioid receptors will be crucial to the development of novel therapeutics that engage the NOP receptor

show abstract

Section: B Bifunctional Compoundssupporting

confidence: 76%

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems

et al. 2016

View full text Add to dashboard Cite

show abstract

“…There was a 10 times potency difference in the ability of Ro 64-6198 to block carrageenan-induced thermal hyperalgesia compared to acute thermal nociception. Studies in rodents show that peripheral inflammation induced by carrageenan or agents like complete Freund's Adjuvant increase expression of nociceptin/orphanin FQ and NOP receptors in primary sensory neurons and spinal cord (Itoh et al 2001; Jia et al 1998). It is also reported in rodents that spinally administered NOP agonists block carrageenan-induced hyperalgesia and nerve-injury induced allodynia in rodents (Obara et al 2005; Sukhtankar et al 2013).…”

Section: Methodsmentioning

confidence: 99%

Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain

et al. 2013

View full text Add to dashboard Cite

Rationale Carrageenan-induced hyperalgesia is a widely used pain model in rodents. However, characteristics of carrageenan-induced hyperalgesia and effects of analgesic drugs under these conditions are unknown in nonhuman primates. Objective The aims of this study were to develop carrageenan-induced hyperalgesia in rhesus monkeys and determine the efficacy and potency of agonists selective for the four opioid receptor subtypes in this model versus acute pain, as compared to NSAIDs. Results Tail-injection of carrageenan produced long-lasting thermal hyperalgesia in monkeys. Systemically administered agonists selective for opioid receptor subtypes i.e. fentanyl (mu/MOP), U-50488H (kappa/KOP), SNC80 (delta/DOP) and Ro 64-6198 (nociceptin/orphanin FQ/NOP) dose-dependently attenuated carrageenan-induced thermal hyperalgesia with different potencies. In absence of carrageenan, these agonists, except SNC80, blocked acute thermal nociception. Opioid-related ligands, especially Ro 64-6198, were much more potent for their antihyperalgesic than antinociceptive effects. Both effects were mediated by the corresponding receptor mechanisms. Only fentanyl produced scratching at antihyperalgesic and antinociceptive doses consistent with its pruritic effects in humans, illustrating a translational profile of MOP agonists in nonhuman primates. Similar to SNC80, systemically administered NSAIDs ketorolac and naproxen dose-dependently attenuated carrageenan-induced hyperalgesia but not acute nociception. Conclusion Using two different pain modalities in nonhuman primates, effectiveness of clinically available analgesics like fentanyl, ketorolac and naproxen was distinguished and their efficacies and potencies were compared with the selective KOP, DOP, and NOP agonists. The opioid-related ligands displayed differential pharmacological properties in regulating hyperalgesia and acute nociception in the same subjects. Such preclinical primate models can be used to investigate novel analgesic agents.

show abstract

“…Carrageenaninduced peripheral inflammation upregulates preproN/OFQ mRNA, N/OFQ peptide, and NOP binding in primary sensory neurones of dorsal root ganglia (Andoh, Itoh, & Kuraishi, 1997;Itoh et al, 2001), and dorsal horn (Fu, Wang, Wang, Yu, & Wu, 2007;Fu, Zhu, Wang, & Wu, 2007) in addition to the hypothalamus (Rosén, Lundeberg, Bytner, & Nylander, 2000) revealing plasticity in the N/OFQ system. Pain patients have elevated serum N/OFQ that is augmented in patients with long-lasting chronic pain (Ko, Kim, Woo, & Kim, 2002), although females with fibromyalgia syndrome have lower plasma N/OFQ (Anderberg, Liu, Berglund, & Nyberg, 1998) suggesting that a correlation between pain and serum N/OFQ may depend on factors such as the presence of inflammation, gonadal steroids, and stress.…”

Section: Nociceptin and Nop Receptor: Relevance To Inflammationmentioning

confidence: 99%

Endogenous Nociceptin System Involvement in Stress Responses and Anxiety Behavior

Fulford

2015

Nociceptin Opioid

View full text Add to dashboard Cite

Induction by carrageenan inflammation of prepronociceptin mRNA in VR1-immunoreactive neurons in rat dorsal root ganglia

Cited by 32 publications

References 23 publications

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems

Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain

Endogenous Nociceptin System Involvement in Stress Responses and Anxiety Behavior

Contact Info

Product

Resources

About